Fradafiban

DB06472ExperimentalSmall molecule

Investigated for use/treatment in angina.

Mechanism: Fradafiban is a glycoprotein IIb/IIIa receptor antagonist. Activation of the platelet glycoprotein (GP IIb/IIIa) receptor on the platelet surface is the final pathway of platelet aggregation that may lead to embolism, which is one on the cause of angina.
Curator reviewed
Primary indication: Investigated for use/treatment in angina.Curator reviewed
Formula / weight: C₂₀H₂₁N₃O₄ · 367.405 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyIKZACQMAVUIGPY-HOTGVXAUSA-NSMILESNC(=N)C1=CC=C(C=C1)C1=CC=C(OC[C@@H]2C[C@@H](CC(O)=O)C(=O)N2)C=C1

Targets

What you can answer from here — as of March 06, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fradafiban, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.